Photo

Photo detail

Stories this photo appears in:

Orexigen Therapeutics Earns $70 Million Milestone Payment

Orexigen Therapeutics Inc. announced it has earned a $70 million milestone payment from partner Takeda Pharmaceuticals related to the shipment of Contrave to pharmacy wholesalers in preparation for commercial launch.

Tease photo

Orexigen Therapeutics Reports First Quarter Results

Orexigen Therapeutics reported a net loss of $24.9 million, or 23 cents per share, for the first quarter ended March 31, compared with a net loss of $19.4 million, or 21 cents per share, for first quarter 2013.

Tease photo

Orexigen Reports Q1 Results

Orexigen Therapeutics reported a net loss of $24.9 million, or 23 cents per share, for the first quarter ended March 31, compared with a net loss of $19.4 million, or 21 cents per share, for first quarter 2013.

Tease photo

FDA to Rule on Orexigen’s Weight-Loss Drug Application By June 10

The Food and Drug Administration said it will review the new drug application for Orexigen Therapeutics Inc.’s weight-loss drug Contrave by June 10.

Tease photo

Orexigen Resubmits Weight-Loss Drug Contrave for FDA Review

La Jolla-based Orexigen Therapeutics Inc. has resubmitted an application with the Food and Drug Administration for its anti-obesity drug, Contrave.

Tease photo

Orexigen Plans $100M Senior Notes Offering

San Diego-based Orexigen Therapeutics Inc. is planning a $100 million offering of convertible senior notes, the company announced.

Tease photo

Orexigen to Resubmit Weight-Loss Pill for FDA Approval

San Diego-based Orexigen Therapeutics Inc. will soon reapply for regulatory approval of its weight-loss pill, Contrave, after reporting that interim results from a large-scale study showed the drug doesn’t significantly increase heart disease risk in patients.

Tease photo